TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9472784
Drug: GR213487B liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR213487B liquid nasal spray (0.4375mg, 4.0mg, or 0.0625mg)
Study: 8543620
Drug: Flow cytometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow cytometry analysis leading to anti-D immunoglobulin administration
Study: 23086971
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet twice daily)
Study: 30635033
Drug: Clazakizumab (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab (subcutaneous administration of 25 mg in monthly intervals)
Study: 8359292
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (ASA, 75 mg daily)
Study: 27247434
Drug: COBRA-light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA-light therapy (prednisolone 30 mg/day, tapered to 7.5 mg/day in 8 weeks and MTX)
Study: 21134017
Drug: Caffeinated alcoholic
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeinated alcoholic beverage (69 mg caffeine/12 oz beer)
Study: 1487551
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 mg three times daily for 3 days)
Study: 1487551
Drug: Acute volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute volume expansion (1500 mL saline in 15 minutes, in supine legs-up position)
Study: 3021488
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg) q.i.d.
Study: 3021488
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg) b.i.d.
Study: 28315450
Drug: Carotenoid supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotenoid supplementation (Macushield™: 10 mg meso-zeaxanthin, 10 mg lutein, 2 mg zeaxanthin)
Study: 25824243
Drug: rhGH (47.6-52.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (47.6-52.4 μg/kg/day) and low-dose stanozolol (20-35 μg/kg/day)
Study: 24317497
Drug: Web-based psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based psychoeducational program (Diapason), 12 weeks duration, weekly sessions
Study: 19484836
Drug: Vascular care
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascular care (treatment according to strict guidelines for hypercholesterolemia and hypertension, including acetylsalicylic acid, folic acid, and pyridoxine)
Study: 9640158
Drug: Thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5 mg kg‐1 (AT‐R group)
Study: 9640158
Drug: Etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.3 mg kg‐1 (AE‐R group)
Study: 3055394
Drug: Perioperative parenteral
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative parenteral cefoxitin (Group A)
Study: 3055394
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral neomycin and erythromycin plus perioperative cefoxitin (Group B)
Study: 3055394
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (cefoxitin) with rectal resections
Study: 3055394
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (neomycin and erythromycin plus cefoxitin) with rectal resections
Study: 3055394
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A patients with longer rectal operations
Study: 3055394
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with rectal resection and operative times of 215 minutes or more
Study: 30920631
Drug: Streptococcus salivarius
Normalized name: Streptococcus salivarius
DrugBank: Streptococcus salivarius (DB19274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray, 2 puffs per nostril twice a day for a week for 3 months
Study: 11323362
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of ropivacaine 2 mg/mL with fentanyl 2 microg/mL (R + F)
Study: 11323362
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of ropivacaine 2 mg/mL without fentanyl (R)
Study: 8394796
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg administered at 7 AM
Study: 8394796
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg administered at 7 PM
Study: 3205554
Drug: 3% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% prilocaine (Citanest) containing 0.03 IU/ml felypressin
Study: 28468736
Drug: Nicotinamide 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide 500 mg/daily
Study: 18492867
Drug: Intensive renal-replacement
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive renal-replacement therapy (intermittent hemodialysis six times per week, sustained low-efficiency dialysis, continuous venovenous hemodiafiltration at 35 ml/kg/hour)
Study: 18492867
Drug: Less-intensive renal-replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less-intensive renal-replacement therapy (intermittent hemodialysis three times per week, continuous renal-replacement therapy at 20 ml/kg/hour)
Study: 18492867
Drug: Intensive renal-replacement
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive renal-replacement therapy
Study: 18492867
Drug: Less-intensive renal-replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less-intensive renal-replacement therapy
Study: 8120158
Drug: Pulse-loading (P-L)
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse-loading (P-L) group received 150 and 200 mg of clomipramine (CMI) on two consecutive evenings, then placebo for 8 days
Study: 8120158
Drug: Traditional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional group began at 50 mg of CMI, followed by gradual increases every second day until 200 mg was reached
Study: 8120158
Drug: Pulse-loading (P-L)
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse-loading (P-L) group
Study: 3321413
Drug: LAF +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LAF + PSA (decontamination, isolation in a laminar air flow room and prophylactic systemic antibiotics)
Study: 3321413
Drug: PSA (prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA (prophylactic systemic antibiotics in a conventional hospital room)
Study: 25645191
Drug: Essential-oil extract
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential-oil extract of Cretan aromatic plants (0.5ml soft gel capsules, twice a day for 7 days)
Study: 25645191
Drug: Placebo (0.5ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5ml olive oil in soft gel capsules)
Study: 11559718
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg daily for 4 months
Study: 11559718
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg daily for 4 months
Study: 3665523
Drug: Calcium entry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium entry blocker nicardipine
Study: 31378952
Drug: Levodopa Benserazide
Normalized name: benserazide / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa Benserazide (LDB) generic preparation (Teva Italia)
Study: 26477840
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab given monthly
Study: 20691834
Drug: rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (10 mg/d)
Study: 7628184
Drug: Omeprazole, 40
Normalized name: Omeprazole, 40 mg oral delayed release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 40 mg/day
Study: 24912456
Drug: STEPPS (Systems
Approvals — FDA: no, EMA: no, PMDA: no
Description: STEPPS (Systems Training for Emotional Predictability and Problem Solving) added to treatment as usual (TAU) for BD
Study: 18826866
Drug: Deferasirox 20
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox 20 mg/kg coadministered with digoxin
Study: 12776949
Drug: Normal-dosage Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-dosage Group (3 mg/kg of heparin)
Study: 10979947
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg/d) for 75 days after BMT
Study: 27739334
Drug: Self-referral to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-referral to inpatient treatment (SRIT)
Study: 18274222
Drug: Low-dose exercise
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose exercise (20 min/day, 5 days/week for 15 weeks)
Study: 18274222
Drug: High-dose exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose exercise (40 min/day, 5 days/week for 15 weeks)
Study: 11384079
Drug: Fosinopril (FOS)
DrugBank: Fosinopril (DB00492)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosinopril (FOS) 10 mg
Study: 11384079
Drug: Captopril (CAP)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CAP) 6.25 mg
Study: 7907184
Drug: Maintaining the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintaining the same dose of the neuroleptic over an extended trial
Study: 7907184
Drug: Significantly increasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Significantly increasing the dose of the same neuroleptic
Study: 6108299
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of lorazepam
Study: 30885824
Drug: No Erythropoietin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Erythropoietin (EPO) treatment (Control)
Study: 28665874
Drug: Single-injection PVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection PVB at T3-T4 level with 25 mL of 0.5% ropivacaine and 4 subcutaneous sham injections
Study: 28665874
Drug: Multiple-injection PVB
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-injection PVB from T1 to T5 level with 5 mL of 0.5% ropivacaine injected at each level
Study: 25005327
Drug: golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 50 mg + MTX
Study: 23861303
Drug: golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 100 mg + MTX (in patients with CRP >1.0 mg/dl)
Study: 15113632
Drug: Breast‐fed and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast‐fed and 1‐ml 30% glucose
Study: 15113632
Drug: Fasting and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting and 1‐ml 30% glucose
Study: 9333792
Drug: Bilevel therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilevel therapy with a fixed inspiratory to expiratory pressure ratio of 1:0.6
Study: 8498624
Drug: 11-lesson curriculum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-lesson curriculum focused on drug resistance skills
Study: 23717119
Drug: Red ginseng
Normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red ginseng (4,500 mg daily for 2 weeks)
Study: 14698695
Drug: Conservative AED
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative AED treatment
Study: 11270479
Drug: Melatonin plus
Normalized name: Nature's Truth Melatonin Plus L-Theanine 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin plus 5-methoxytryptamine (1 mg/day orally in the early afternoon)
Study: 9252932
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot (3.75 mg once monthly)
Study: 24282477
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg caffeine
Study: 12618736
Drug: Drugs (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs (90 patients)
Study: 10883557
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT), 7-week group intervention
Study: 6431211
Drug: Milacemide 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milacemide 400 mg
Study: 6431211
Drug: Milacemide 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milacemide 800 mg
Study: 6431211
Drug: Milacemide 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milacemide 1600 mg
Study: 6431211
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 600 mg
Study: 3370078
Drug: Piracetam 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 1600 mg
Study: 30788925
Drug: Dicycle (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicycle (Group B: dexamethasone 40 mg once a day, from day 1 to day 4, day 15 to day 18)
Study: 30788925
Drug: Tri-cycle (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-cycle (Group C: dexamethasone 40 mg once a day, from day 1 to day 4, day 15 to day 18, day 29 to day 32)
Study: 25171270
Drug: Daily protein
Normalized name: Supra Clens Daily Protein Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily protein intake (DPI) above the median (mean DPI of >1 g/kg)
Study: 23207335
Drug: Entecavir monotherapy
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir monotherapy for 3 years
Study: 23207335
Drug: Control (non‐antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non‐antiviral treatment)
Study: 9708959
Drug: Tolcapone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone (both doses)
Study: 2309541
Drug: Midazolam 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.4 mg/kg rectally as premedication
Study: 6804244
Drug: desmethyldiazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: desmethyldiazepam (20 mg/kg/day) for one week
Study: 31519550
Drug: Very-low-phosphate diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-phosphate diet (phosphate-to-protein ratio of 8 mg/g)
Study: 31519550
Drug: Low-phosphate diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-phosphate diet (phosphate-to-protein ratio of 10 mg/g)
Study: 29280664
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement with stevia and L-carnitine
Study: 24679851
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied to the irradiated side of the face after surgery
Study: 20062928
Drug: DZ-697b 360
Normalized name: DA-697b
DrugBank: DA-697b (DB06001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZ-697b 360 mg
Study: 7755941
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg verapamil (V) twice a day
Study: 7755941
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (T and V)
Study: 15107971
Drug: Everolimus 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 1.5 mg
Study: 15107971
Drug: Everolimus 3
Normalized name: everolimus 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 3 mg
Study: 29084336
Drug: s-lactam plus
Normalized name: casanthranol / docusate sodium Oral Capsule [Docusoft-S Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: s-lactam plus macrolide combination therapy
Study: 29084336
Drug: s-lactam monotherapy
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: s-lactam monotherapy
Study: 26114161
Drug: Experimental therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental therapy (bevacizumab)
Study: 21723554
Drug: Active tablets
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tablets containing 3.4 mg of VPP and IPP
Study: 16752625
Drug: Mandibular overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdentures retained by 2 endosseous implants
Study: 21195291
Drug: Carthami-Semen (CS)
Normalized name: Hippocastani semen
DrugBank: Horse chestnut (DB13195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carthami-Semen (CS) acupuncture point injection
Study: 21195291
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) acupuncture point injection
Study: 19446152
Drug: Clopidogrel besylate
Normalized name: Clopidogrel besylate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel besylate (300 mg loading dose, 75 mg/d maintenance dose)
Study: 19446152
Drug: Clopidogrel bisulfate
Normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel bisulfate (300 mg loading dose, 75 mg/d maintenance dose)
Study: 19446152
Drug: Both clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both clopidogrel preparations
Study: 15628250
Drug: Ultrasound with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound with standard gel
Study: 9252710
Drug: Lentinan administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lentinan administration
Study: 31090212
Drug: Commonly prescribed
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commonly prescribed drugs
Study: 27458307
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus ipilimumab
Study: 26305052
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 30 days
Study: 26305052
Drug: Resveratrol 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 75 mg twice daily for 30 days
Study: 23686786
Drug: Caffeine/Ephedrine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine/Ephedrine (200 mg caffeine/20 mg ephedrine t.i.d.)
Study: 17159824
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen therapy (2 mg daily)
Study: 15223106
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (oral and transdermal)
Study: 29397354
Drug: Napabucasin 480
Normalized name: Napabucasin
DrugBank: Napabucasin (DB12155)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Napabucasin 480 mg taken orally every 12 hours
Study: 24930587
Drug: Chlorophyll-a photodynamic
Normalized name: CHLOROPHYLL A
DrugBank: Chlorophyll A (DB02133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorophyll-a photodynamic therapy (8 treatment sessions over 4 weeks)
Study: 3965439
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of haloperidol
Study: 6356911
Drug: Aspirin, Indomethacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, Indomethacin, Placebo
Study: 26911397
Drug: Adherence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence therapy (six sessions in addition to usual care)
Study: 19899321
Drug: noMR group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: noMR group (n = 40) - only an intubation dose of cisatracurium (0.15 mg kg(‐1)) was administered
Study: 19899321
Drug: MR group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR group (n = 40) - continuous infusion of muscle relaxant added to the intubation dose
Study: 17642451
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Group B, n=30)
Study: 15100698
Drug: Ketamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine at 50 ng/ml plasma concentration
Study: 15100698
Drug: Ketamine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine at 100 ng/ml plasma concentration
Study: 11246934
Drug: Anhydrous crystalline
Normalized name: Mesembryanthemum crystallinum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anhydrous crystalline maltose (ACM) 200 mg lozenge, administered three times daily for 12 weeks (study Alpha)
Study: 11246934
Drug: Anhydrous crystalline
Normalized name: Mesembryanthemum crystallinum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anhydrous crystalline maltose (ACM) 200 mg lozenge, administered three times daily for 24 weeks (study Omega)
Study: 9674458
Drug: Sparfloxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin, 400 mg on day 1, then 200 mg once daily for 10 days
Study: 8033429
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy and/or relapse
Study: 23642943
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 placebo soft gels)
Study: 21091683
Drug: Topical nadifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nadifloxacin 1% cream
Study: 21091683
Drug: Topical erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical erythromycin 4% gel
Study: 18206946
Drug: Alarm treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alarm treatment following pretreatment with antimuscarinics and/or holding exercises
Study: 17067352
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment
Study: 9333973
Drug: Orthopedic Horseback‐Riding‐Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthopedic Horseback‐Riding‐Therapy (OHRT)
Study: 8500515
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg bumethanide at 0800 and 1200 (treatment 1)